GastroenterologyNews.net

Gastroenterology Xagena

Xagena Mappa
Medical Meeting
Onco News
Ematobase.it

Adalimumab ( Humira ) is effective for induction and maintenance of remission in patients with moderate to severe ulcerative colitis. Researchers have assessed whether Adalimumab, in addition to sta ...


Diverticulitis is a common disease. Recent changes in understanding its natural history have substantially modified treatment paradigms. It has been reviewed the etiology and natural history of div ...


The safety and efficacy of Adalimumab ( Humira ) for patients with moderately to severely active ulcerative colitis has been reported up to week 52 from the placebo-controlled trials ULTRA ( Ulcerativ ...


Postoperative pancreatic fistula is a major contributor to complications and death associated with pancreatic resection. Pasireotide ( Signifor ), a somatostatin analogue that has a longer half-life t ...


Tofacitinib ( Xeljanz ), an orally administered Janus kinase inhibitor, blocks signaling through gamma-chain-containing cytokines ( interleukins 2, 4, 7, 9, 15, and 21 ). Researchers have performed ...


Eli Lilly has announced that the FDA ( Food and Drug Administration ) has approved Cyramza ( Ramucirumab ) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastro ...


The alpha4beta7 integrin monoclonal antibody Vedolizumab ( Entyvio ) is hypothesised to be gut selective. Effects of Vedolizumab on immune responses to parenterally or enterally administered antigens ...


The objective of a study was to compare high-definition white-light endoscopy ( HDWLE ) alone with random biopsy ( RB ) and HDWLE plus eCLE ( endoscope-based confocal laser endomicroscopy system ) and ...


Metastatic colorectal cancer ( mCRC ) is commonly treated with 5-Fluorouracil, Folinic acid, and Oxaliplatin or Irinotecan. The multitargeted kinase inhibitor, Regorafenib ( Stivarga ), was combined ...


Information on efficacy and predictors of response to Adalimumab ( Humira ) in ulcerative colitis clinical practice is limited. The aim of study was assessed the response to Adalimumab and its pred ...


Optimizing anti-tumor necrosis factor therapy is often required in patients with Crohn's disease. In case of partial response or loss of response to Adalimumab ( Humira ) 40 mg every other week, the i ...


Vedolizumab ( Entyvio ) is a humanized monoclonal antibody that inhibits adhesion and migration of leukocytes into the gastrointestinal tract by preventing the alpha4beta7 integrin subunit from bindin ...


A new generation of oral anticoagulants ( nOAC ), which includes thrombin and factor Xa inhibitors, has been shown to be effective, but little is known about whether these drugs increase patients' ris ...


In the past decades, prophylactic colectomy to prevent development of colorectal cancer substantially has improved prognosis in patients with familial adenomatous polyposis ( FAP ). The mortality patt ...


A phase III clinical trial of the drug Abraxane ( nanoparticle albumin-bound Paclitaxel; Nab-Paclitaxel ) in combination with current standard of care Gemcitabine ( Gemzar ) in patients with advanced ...